NCAPH

Across TCGA pan-cancer cohorts, NCAPH mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NCAPH data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher NCAPH mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NCAPH expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where NCAPH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.891	0.503	<.001	34	view →
PDAC	OS	Quartile	III,IV	0.585	0.973	.003	19	view →
LUAD	OS	Tertile	All	0.583	0.842	.012	15	view →
CCRCC	OS	Median	III,IV	0.485	1.000	.036	2	view →
GBM	DFS	Median	All	0.678	0.755	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NCAPH–LSCC (DFS)

Open the LSCC breakdown →